The landscape of cancer care is shifting from reactive treatment to proactive, data-driven management. As molecular diagnostics become the cornerstone of modern medicine, the Cancer Biomarkers Market Opportunities are expanding into high-growth territories. With the market size expected to reach US$ 83.9 billion by 2031 and a projected CAGR of 10.8% from 2025 to 2031, the potential for...